Press release

Release
21.09.2020

VALBIOTIS selected to present 3 studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD)

Download
Release
14.09.2020

VALBIOTIS receives US and European TOTUM-070 patent for reducing hypercholesterolemia

Download
Release
03.08.2020

Provision of the Registration Document (R.20-018) (in French)

Download
Release
31.07.2020

Half year report of the liquidity contract – July 2020 (in French)

Download
Release
28.07.2020

VALBIOTIS announces a cash position of €10.9M at 30 June 2020

Download
Release
17.07.2020

VALBIOTIS opens up its capital to a new shareholder: AMIRAL GESTION

Download
Release
15.07.2020

VALBIOTIS announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study on TOTUM-63 to reduce Type 2 Diabetes risk factors

Download
Release
08.07.2020

VALBIOTIS: authorization to launch the international Phase II/III REVERSE-IT clinical study on TOTUM-63, to reduce Type 2 Diabetes risk factors

Download
Release
12.06.2020

VALBIOTIS selected at the 80th Scientific Sessions of the American Diabetes Association to present Phase II clinical results of TOTUM-63 in prediabetes

Download